Acquired Anemias: Iron Deficiency, Cobalamin Deficiency, and Autoimmune Hemolytic Anemia

Evidence-Based Hematology

Volumn , Issue , 2009, Pages 197-205

  Zumberg, Marc S ^a   Kahn, Marc J ^b   Lottenberg, Richard ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired anemias; Autoimmune hemolytic anemia (AIHA); Cobalamin (B12) deficiency; Grading evidence and recommendations; Intravenous iron to oral iron salts in patient populations; Iron deficiency anemia; Oral cobalamin replacement for patients with cobalamin deficiency; Role of measurement of homocysteine and methylmalonic acid in assessment; Role of rituximab in WAIHA

Indexed keywords

EID: 78149325139     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300857.ch24     Document Type: Chapter

References (66)

1. Guyatt G, Schunemann HJ, Cook D, et al. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCPConference onAntithrombotic and Thrombolytic Therapy. Chest. 2004;126:179S-87S.
2. Hallberg L, Ryttinger L, Solvell L. Side-effects of oral iron therapy: a double-blind study of different iron compounds in tablet form. Acta Med Scand Suppl. 1966;459:3-10.
3. Wingard RL, Parker RA, Ismail N, et al. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25:433-39.
4. Jacobs P,Wormald LA,Gregory MC. Absorption of iron polymaltose and ferrous sulphate in rats and humans: a comparative study. S AfrMed J. 1979;55:1065-72.
5. Jacobs P, Fransman D, Coghlan P. Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood donors. J Clin Apher. 1993;8:89-95.
6. Aronstam A, Aston DL. A comparative trial of a controlled-release iron tablet preparation ("Ferrocontin" Continus) and ferrous fumarate tablets. Pharmatherapeutica. 1982;3:263-67.
7. Brock C, Curry H, Hanna C, et al. Adverse effects of iron supplementation: a comparative trial of a wax-matrix iron preparation and conventional ferrous sulfate tablets. Clin Ther. 1985;7:568-73.
8. Elwood PC,Williams G. A comparative trial of slow-release and conventional iron preparations. Practitioner. 1970;204:812-15.
9. Rybo G, Solvell L. Side-effect studies on a new sustained release iron preparation. Scand J Haematol. 1971;8:257-64.
10. Sas G,Nemesanszky E, Brauer H, et al. Onthe therapeutic effects of trivalent and divalent iron in iron deficiency anaemia. Arzneimittelforschung. 1984;34:1575-79.
11. Devasthali SD, Gordeuk VR, Brittenham GM, et al. Bioavailability of carbonyl iron: a randomized, double-blind study. Eur J Haematol. 1991;46:272-78.
12. Gordeuk VR, Brittenham GM,Hughes M, et al. High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial. Am J Clin Nutr. 1987;46:1029-34.
13. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980;243:1726-31.
14. Silverstein SB,Rodgers GM. Parenteral iron therapy options. AmJHematol. 2004;76:74-8.
15. Michael B,Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830-39.
16. Michael B, Coyne DW, Folkert VW, et al. Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety. Nephrol Dial Transplant. 2004;19:1576-80.
17. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. AmJKidneyDis. 1999;33:464-70.
18. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378-82.
19. Kosch M, Bahner U, Bettger H, et al. A randomized, controlled parallelgroup trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treatedwithrHuEpo. Nephrol Dial Transplant. 2001;16:1239-44.
20. Laman CA, Silverstein SB, Rodgers GM. Parenteral iron therapy: a single institution's experience over a 5-year period. J Natl Compr Canc Netw. 2005;3:791-95.
21. Eichbaum Q, Foran S, Dzik S. Is iron gluconate really safer than iron dextran? Blood. 2003;101:3756-57.
22. Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26:445-54.
23. Aggarwal HK, Nand N, Singh S, et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India. 2003;51:170-74.
24. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100: c55-c62.
25. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16:967-74.
26. Van Wyck DB, Roppolo M,MartinezCO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846-56.
27. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301-7.
28. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231-42.
29. Schroder O,Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patientswith inflammatory bowel disease-a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503-9.
30. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005;40:1058-65.
31. Al RA, Unlubilgin E, Kandemir O, et al. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol. 2005;106:1335-40.
32. Bayoumeu F, Subiran-Buisset C, Baka NE, et al. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol. 2002;186:518-22.
33. Singh K, Fong YF, Kuperan P. A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy. Eur J Haematol. 1998;60:119-24.
34. Al-Momen AK, al-Meshari A, al-Nuaim L, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996;69:121-24.
35. Rimon E, Levy S, Sapir A, et al. Diagnosis of iron deficiency anemia in the elderly by transferrin receptor-ferritin index. Arch Intern Med. 2002;162:445-49.
36. Chen YC,Hung SC, Tarng D.C. Association between transferrin receptorferritin index and conventional measures of iron responsiveness in hemodialysis patients. Am J Kidney Dis. 2006;47:1036-44.
37. Choi JW. Sensitivity, specificity, and predictive value of serum soluble transferrin receptor at different stages of iron deficiency. Ann Clin Lab Sci. 2005;35:435-39.
38. Lee EJ, Oh EJ, Park YJ, et al. Soluble transferrin receptor (sTfR), ferritin, and sTfR/log ferritin index in anemic patients with nonhematologic malignancy and chronic inflammation. Clin Chem. 2002;48:1118-21.
39. Savage DG, Lindenbaum J, Stabler SP, et al. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med. 1994;96: 239-46.
40. Clarke R, Refsum H, Birks J, et al. Screening for vitamin B-12 and folate deficiency in older persons. Am J Clin Nutr. 2003;77:1241-1247.
41. Bolann BJ, Solli JD, Schneede J, et al. Evaluation of indicators of cobalamin deficiency defined as cobalamin-induced reduction in increased serum methylmalonic acid. Clin Chem. 2000;46:1744-50.
42. Kuzminski AM, Del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998;92:1191-98.
43. Lane LA,Rojas-Fernandez C. Treatmentof vitamin B(12)-deficiency anemia: oral versus parenteral therapy. Ann Pharmacother. 2002;36:1268-72.
44. Bowdler AJ. The role of the spleen and splenectomy in autoimmune hemolytic disease. Semin Hematol. 1976;13:335-48.
45. Allgood JW, Chaplin H Jr. Idiopathic acquired autoimmune hemolytic anemia: a review of forty-seven cases treated from 1955 through 1965. Am J Med. 1967;43:254-73.
46. Schwartz SI, Bernard RP, Adams JT, et al. Splenectomy for hematologic disorders. Arch Surg. 1970;101:338-47.
47. Coon WW. Splenectomy in the treatment of hemolytic anemia. Arch Surg. 1985;120:625-28.
48. Balague C, Targarona EM, Cerdan G, et al. Long-term outcome after laparoscopic splenectomy related to hematologic diagnosis. Surg Endosc. 2004;18:1283-87.
49. Gibson J. Autoimmune hemolytic anemia: current concepts. Aust N Z J Med. 1988;18:625-37.
50. Pirofsky B, Bardana EJ Jr. Autoimmune hemolytic anemia. II. Therapeutic aspects. Ser Haematol. 1974;7:376-85.
51. Katkhouda N, Hurwitz MB, Rivera RT, et al. Laparoscopic splenectomy: outcome and efficacy in 103 consecutive patients. Ann Surg. 1998;228:568-78.
52. Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. 1999;61:98-102.
53. King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol. 2005;42:131-36.
54. Narat S, Gandla J, Hoffbrand AV, et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica. 2005;90:1273-74.
55. Shanafelt TD, Madueme HL, Wolf RC, et al. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003;78:1340-46.
56. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857-61.
57. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358: 1511-13.
58. Heidel F, Lipka DB, von AC, et al. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost. 2007;97:228-33.
59. Ramanathan S, Koutts J, Hertzberg MS. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol. 2005;78:123-26.
60. Flores G, Cunningham-Rundles C, Newland AC, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993;44: 237-42.
61. Sherer Y, Levy Y, Fabbrizzi F, et al. Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg)-report of seven cases and review of the literature. Eur J InternMed. 2000;11:85-88.
62. Besa EC. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. Am J Med. 1988;84:691-98.
63. Mitchell CA, Van der Weyden MB, Firkin BG. High dose intravenous gammaglobulin in Coombs positive hemolytic anemia. Aust N Z J Med. 1987;17:290-94.
64. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. TransfusMed Rev. 2007;21:S9-S56.
65. Berentsen S,Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in patients. Blood. 2004;103:2925-28.
66. Schollkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47:253-60.